As the founder of DNA Healthcare Solutions, Mr. Kutrucz is the principal driving force responsible for the company’s development in becoming a leader in molecular infectious disease on a global level keeping testing accurate, affordable, and available.
Mr. Kutrucz has over sixteen years of experience in molecular laboratory services, focusing the last six on human infectious disease testing and antimicrobial stewardship programs. Kutrucz is responsible for developing novel tests, molecular diagnostic application education, business strategies, and vision for the network of companies he owns. Kutrucz continues to grow his companies in animal healthcare, pharmaceuticals, bioinformatics, and CLIA accredited laboratories. In the human infectious disease market, Mr. Kutrucz is a part owner of an international pharmaceutical manufacturing facility, several international laboratories, a bioinformatics/LIS company, and an international medical supply factory. He uses his companies to understand infectious diseases across species, including plants and animals, and finds solutions to help reduce cost for diagnostic testing and treatment.
Mr. Kutrucz has had the privilege to work alongside Dr. Matthew Regulski. Dr. Regulski is a leader in wound care and understanding infectious diseases in biofilm. He has written several papers and leads talks throughout the US and Europe about biofilm and treating infectious diseases in wound care. Dr. Regulski worked with Kutrucz for a year on crafting and fine tuning the first Wound Surgical panel for humans. This, along with other novel, comprehensive panels, has set Kutrucz apart in his field in providing providers clinically actionable testing and reporting. The education and implementation of both the technology and reporting has been a critical component to saving patient lives from 8 weeks to 107 years of age. Along with this, Kutrucz has been a leader in driving the technology and antibiotic stewardship program to combat the current Coronavirus concern. Using strategic partners, including Bill Gates and Melinda Gates Foundation, UPS, Amazon, and MedVantx, Kutrucz has assembled a team of professionals to undertake an end-to-end solution where 30,000 to 250,000 patient samples can be assessed in a day and the right antibiotic can be delivered to the septic patient’s home within 24 hours. His knowledge and organization positions him to being one of the only individuals to approach the Coronavirus concern with a plan to calm the markets and save patient lives.
Mr. Kutrucz graduated from the University of Florida and the University of Miami with a background in molecular biology and critical care nursing. Kutrucz has lectured for over four years at the University of Florida on molecular technology techniques, as well as animal & plant molecular genetics. Kutrucz previously served as a Biological Scientist for the Education & Training Department at The University of Florida Interdisciplinary Center for Biotechnology Research (ICBR). Kutrucz’ clinical experience has developed through his years working as a Critical Care Nurse in trauma, ICU, and emergency departments throughout Florida.
Mr. Kutrucz has taken the challenges of many roles at different levels of biotechnology companies, including CSO at Volente Healthcare, COO at DNA Neurodiagnostic Technology, and VP of Laboratory Operations for Volente Diagnostics/AIT Healthtracks.
Now as an owner of multiple companies, Mr. Kutrucz continues to meet the challenges of the healthcare market. He remains committed to advancing his vision with the diagnostics of infectious disease testing for patients, clinicians, and payors.